Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 2022
Neoleukin Therapeutics (NASDAQ:NLTX) announced it will report its second quarter 2022 financial results on August 9, 2022, following the market's close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Neoleukin Therapeutics (NASDAQ:NLTX) announced it will report its second quarter 2022 financial results on August 9, 2022, following the market's close. A conference call and live audio webcast will be held at 1:30 p.m. Pacific / 4:30 p.m. Eastern. Participants can join via toll-free number (800) 715-9871 with conference ID 4116795. The archived audio will be available for replay on their Investor Relations website shortly after the event.
Neoleukin focuses on developing advanced immunotherapies for cancer and autoimmunity using innovative de novo protein design.
Positive
- Upcoming financial results announcement may indicate growth and insights into future outlook.
- Lead product candidate NL-201 is designed to offer improved tolerability and efficacy.
Negative
- None.
Details
News Market Reaction – NLTX
The recorded move for NLTX in the trading session of this news was -1.87%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, July 27, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin” (NASDAQ:NLTX), today announced it will report second quarter 2022 financial results on Tuesday, August 9, 2022 after the close of financial markets and then host a conference call and live audio webcast to discuss these results and provide a corporate update. Details of the event are as follows:
Date: Tuesday, August 9, 2022
Time: 1:30 p.m. Pacific / 4:30 p.m. Eastern
Toll-free: (800) 715-9871
Conference ID: 4116795
Webcast URL: http://investor.neoleukin.com/events
The archived audio webcast will be available on the Investor Relations section of the Neoleukin website approximately two hours after the event and will be available for replay for at least 30 days after the event.
About Neoleukin Therapeutics, Inc.
Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Neoleukin’s lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface. For more information, please visit the Neoleukin website: www.neoleukin.com.
Contacts:
Media
Julie Rathbun
206-769-9219
jrathbun@neoleukin.com
Investors
Solebury Trout
Alexandra Roy
617-221-9197
aroy@soleburytrout.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.